SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published erratum appears in N Engl J Med 2006;355:221]. N Engl J Med 2005; 352: 1092102.
  • 2
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 47581.
  • 3
    Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction [published erratum appears in Arch Intern Med 2002;162:1858]. Arch Intern Med 2002; 162: 11115.
  • 4
    Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 11823.
  • 5
    Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 30006.
  • 6
    Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099104.
  • 7
    Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam study. Arch Intern Med 2002; 162: 26570.
  • 8
    Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14: 2406.
  • 9
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160: 77784.
  • 10
    Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 17516.
  • 11
    Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005; 330: 1370.
  • 12
    Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? [review]. Lancet 1999; 354: 12024.
  • 13
    Pilote L, Lavoie F, Ho V, Eisenberg MJ. Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988–1995. CMAJ 2000; 163: 316.
  • 14
    Goff DC Jr, Pandey DK, Chan FA, Ortiz C, Nichaman MZ, and the Corpus Christi Heart Project. Congestive heart failure in the United States: is there more than meets the I(CD code)? Arch Intern Med 2000; 160: 197202.
  • 15
    Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 2003; 108: 18491.
  • 16
    Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 9991009.
  • 17
    Robins JM, Gail MH, Lubin JH. More on “Biased selection of controls for case-control analyses of cohort studies.” Biometrics 1986; 42: 2939.
  • 18
    RothmanKJ, GreenlandS, editors. Modern epidemiology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1998.
  • 19
    WHO Collaborating Centre for Drug Statistics. URL: http://www.whocc.no/atcddd.
  • 20
    Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003; 106: 40915.
  • 21
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 2000; 284: 124755.
  • 22
    Data presented to the FDA Arthritis Advisory Committee, February 2001. URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf.
  • 23
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 24
    Data presented to the FDA Arthritis Advisory Committee, February 2001. URL: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf.
  • 25
    Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood-pressure. Arch Intern Med 1993; 153: 47784.
  • 26
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood-pressure? A meta-analysis. Ann Intern Med 1994; 121: 289300.
  • 27
    Wing LM, Bune AJ, Chalmers JP, Graham JR, West MJ. The effects of indomethacin in treated hypertensive patients. Clin Exp Pharmacol Physiol 1981; 8: 53741.
  • 28
    Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients. Clin Exp Hypertens A 1984; 6: 107793.
  • 29
    Wolfe F, Zhao S, Reynolds M, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 2004; 31: 114351.
  • 30
    Sowers JR, White WB, Pitt B, Whelton A, Sinion LS, Winer N, et al, and the Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus [published erratum appears in Arch Intern Med 2005;165:551]. Arch Intern Med 2005; 165: 1618.
  • 31
    Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 148892.
  • 32
    Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease [review]. Arthritis Rheum 2004; 50: 240014.
  • 33
    Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004; 57: 13141.
  • 34
    Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 41321.
  • 35
    Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 75638.
  • 36
    FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 43342.
  • 37
    Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class [abstract]. Ann Rheum Dis 2005; 64 Suppl 3: 263.
  • 38
    Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology 2005; 16: 1724.
  • 39
    Tamblyn R, Abrahamowicz M. Drug utilization patterns. In: ArmitageP, ColtonT, editors. Encyclopedia of biostatistics. West Sussex (UK): J Wiley; 1998. p. 123547.